Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp insertion in exon2.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IFI6, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IFI6 also known as Interferon Alpha-Inducible Protein 6 is a 130-amino acid protein with a mass of approximately 14.7 kDa. This protein locates itself in the mitochondrial outer membrane and is expressed abundantly in tissues such as the liver muscle and kidney. The expression of IFI6 increases in response to interferon treatment especially interferons alpha and beta.
Biological function summary
IFI6 plays a role in apoptotic resistance mechanisms helping cells to avoid programmed death under stress conditions. This protein does not function as part of any large complex but operates independently to regulate apoptosis by controlling the mitochondrial membrane potential. Its involvement in cellular growth and immune response proves significant especially in viral infections where it modulates the cell's response to viral replication.
Pathways
IFI6 integrates into the interferon signaling pathway which is important in defending against viral infections. It collaborates with other proteins such as STAT2 and IRF9 to activate immune responses. Moreover IFI6 influences the apoptosis pathway where it interacts with anti-apoptotic proteins like Bcl-2 to support cell survival under certain conditions.
IFI6 is implicated mainly in viral infections and cancer. Its expression levels can affect viral persistence during infections such as hepatitis C. In cancer IFI6 has been observed in the context of melanoma where it interacts with proteins like Bcl-2 to potentially alter cancer cell survival and resistance to therapies. Understanding IFI6's role may hold importance for developing targeted treatments in such conditions.
